NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

自閉症:競爭情形 (到2026年)

Autism - Competitive Landscape to 2026

出版商 GlobalData 商品編碼 995608
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
自閉症:競爭情形 (到2026年) Autism - Competitive Landscape to 2026
出版日期: 2020年10月30日內容資訊: 英文 45 Pages
簡介

自閉症的治療藥的開發平台醫藥品,現在有44種產品在臨床實驗中,其中的5種以大麻素受體作為標的。由於臨床實驗的後期階段的開發中產品獲承認,今後6年促進市場成長。

本報告提供自閉症醫藥品的開發、上市趨勢預測相關分析,目前治療環境,及主要成藥、開發平台醫藥品的概要,臨床實驗的進展,各種產品的上市可能性,社群媒體和數位行銷的活用狀況,主要企業的產品開發、策略展開的動向等資訊彙整,為您概述為以下內容。

目錄

第1章 目錄

第2章 摘要整理

第3章 簡介

  • 分析範圍
  • 流行病學概要
  • 流行病學

第4章 成藥的評估

  • 成藥概要
  • 成藥的簡介

第5章 開發平台醫藥品的評估

  • 開發平台醫藥品概要
  • 開發平台醫藥品:各地區的明細
  • 開發平台醫藥品:各分子類型、各標的的明細
  • 優先的審查的指定的可能性
  • 相變的成功率
  • 核準的可能性

第6章 臨床試驗的評估

  • 臨床試驗概要:各相 (各期)
  • 各地區的概要
  • 治療領域的展望
  • 主要贊助商 (資金提供者)
  • 登記情形分析
  • 實行可能性分析

第7章 商業性評估

  • 今後的市場促進因素

第8章 社群媒體與數位行銷

  • 有力的Twitter Chatter
  • 知名品牌藥企業的網站
  • 信任來源和引用來源

第9章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC028CL

GlobalData's "Autism - Competitive Landscape to 2026" combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Cannabinoid receptors and Gamma-aminobutyric Acid (GABA) receptors are the major focus of drug developers. There are 44 drugs in the pipeline, five of which targets cannabinoid receptor. Big Pharma dominates R&D in this indication, with Otsuka, Teva Pharmaceuticals, and Zelira Therapeutics leading the way. The increasing awareness and approval of late-stage pipeline molecules will drive the market growth over the next six years, but lack of curative treatment and increasing generic penetration will limit the growth.

This report provides a data-driven overview of the current and future competitive landscape in autism therapeutics.

Scope

Components of the report include -

  • Disease epidemiology
  • Marketed drugs assessment
  • Pipeline drugs assessment
  • Clinical trials assessment
  • Commercial assessment
  • Social media overview
  • Digital marketing overview

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global autism market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global autism market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Table of Contents

  • 1.1 Preface
  • 1.2 Abbreviations
  • 1.3 Related Reports
  • 1.4 Upcoming Related Reports

2 Executive Summary

  • 2.1 Key Findings
  • 2.2 Key Events

3 Introduction

  • 3.1 Report Scope
  • 3.2 Disease Overview Epidemiology Overview
  • 3.3 Epidemiology

4 Marketed Drugs Assessment

  • 4.1 Marketed Drugs Overview
  • 4.2 Marketed Drug Profiles

5 Pipeline Assessment

  • 5.1 Pipeline Overview
  • 5.2 Pipeline Breakdown by Region
  • 5.3 Pipeline Breakdown by Molecule Type and Target
  • 5.4 Drug Review Designations
  • 5.5 Phase Transition Success Rates
  • 5.6 Likelihood of Approval

6 Clinical Trial Assessment

  • 6.1 Clinical Trials Overview by Phase
  • 6.2 Overview by Region
  • 6.4 Therapy Area Perspective
  • 6.4 Leading Sponsors
  • 6.5 Enrollment Analytics
  • 6.6 Feasibility Analysis

7 Commercial Assessment

  • 7.1 Upcoming Market Catalysts

8 Social Media and Digital Marketing

  • 8.1 Key Twitter Chatter
  • 8.2 Top Branded Websites
  • 8.3 Trust Flow and Citation Flow

9 Appendix

  • 9.1 Methodology
  • 9.2 About the Authors
  • 9.3 About GlobalData
  • 9.4 Contact Us
  • 9.5 Disclaimer